S-1: Turn Therapeutics Files S-1 for Direct Nasdaq Listing

Turn Therapeutics Inc., a pharmaceutical and medical device development company, files an S-1 registration statement for a direct listing on Nasdaq, focusing on its proprietary PermaFusion platform for dermatology and vaccine programs.

Summary

• Turn Therapeutics is a pharmaceutical and medical device development company built around its proprietary PermaFusion platform technology, designed to enhance drug performance by enabling stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without emulsifiers.
• The PermaFusion platform has been validated across multiple FDA-cleared medical devices, and its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis.
• The Hexagen formula, based on PermaFusion, has received three FDA 510(k) clearances (K160872 in 2016 for wounds, K171191 in 2017 for dermatitis, and K183681 in 2019 for antimicrobial gauze).
• The company is currently not generating revenue from these devices, as it focuses internal efforts on drug development of its core technology.
• The GX-03/Hexagen drug candidate for eczema and onychomycosis is based on polyhexanide (PHMB), a new chemical entity (NCE) with demonstrated antimicrobial, anti-inflammatory, and immunomodulating properties.
• The FDA has provided a regulatory pathway allowing the company to bypass Phase 2 studies and proceed directly to pivotal Phase 3 trials for eczema and onychomycosis, leveraging existing 510(k) clinical data.
• A Phase 2-equivalent, 114-patient double-blind, randomized, vehicle-controlled trial for moderate-to-severe eczema commenced patient dosing in mid-July 2025.
• In collaboration with a global non-profit, the company is developing thermostable, intranasal vaccines, achieving 100% recovery of a live VSV-based vaccine vector after 72 hours at room temperature (May 2025) and 100% recoverability of a Marburg vaccine candidate for up to 14 days in ambient storage and 28 days in refrigerated storage (June 2025).
• Preclinical in-vivo xenograft studies showed an 85% reduction in viral load for herpes zoster ophthalmicus (shingles of the eye) and an approximate 29% reduction in tumor size compared to placebo (20% vs. 5-Fluorouracil) for basal cell carcinoma.
• MiMedx Group, Inc. licensed rights to the FleX Product (a combination collagen powder/Hexagen product for wound and burn care) in November 2022, with potential milestone payments up to $69.55 million and mid-single digit royalties on net sales. MiMedx is pursuing a De Novo classification pathway for the FleX Product.
• The company reported net losses of $1.57 million for the six months ended June 30, 2025, and $1.77 million for the year ended December 31, 2024, with an accumulated deficit of $20.76 million as of June 30, 2025.
• Cash and cash equivalents were $3.19 million as of June 30, 2025, with an estimated operational runway into the fourth quarter of 2025.
• A material weakness in internal control over financial reporting related to stock-based compensation accounting was identified.
• The company intends to change its name from Global Health Solutions, Inc. to Turn Therapeutics Inc. immediately prior to the effectiveness of the registration statement and has applied for listing its common stock on Nasdaq under the symbol TTRX.
• Founder and CEO, Bradley Burnam, will control more than 50% of the outstanding common stock, making the company a 'controlled company' under Nasdaq rules, which allows for exemptions from certain corporate governance requirements.

Sentiment

Score: 3

Explanation: While the company has promising technology and positive preclinical/early clinical data, significant financial losses, a short cash runway, and substantial doubt about its going concern status, coupled with the inherent risks of a direct listing and reliance on future capital raises, indicate a highly speculative and risky investment.

Positives

• Proprietary PermaFusion platform offers broad formulation capabilities across multiple therapeutic categories, enhancing drug performance and bioavailability while reducing API load and adverse events.
• The Hexagen formula has received three FDA 510(k) clearances for medical devices in wound care and dermatitis management, demonstrating technical proof of concept and therapeutic effects.
• FDA has confirmed a regulatory pathway allowing the company to bypass Phase 2 studies and proceed directly to pivotal Phase 3 trials for eczema and onychomycosis, potentially accelerating drug development.
• Positive preclinical and clinical data for GX-03 in eczema models showed a 67% reduction in Investigators Global Assessment (IGA) scores within 7 days and significant inhibition of key inflammatory cytokines (IL-36, IL-31, IL-4) with no reported adverse events.
• In-vivo data for onychomycosis demonstrated effective penetration of fungal nails and elimination of dermatophytes, clinically differentiating the candidate from conventional topical therapies.
• The vaccine delivery platform achieved 100% recovery of a live VSV-based vaccine vector after 72 hours at room temperature and 100% recoverability of a Marburg vaccine candidate for up to 14 days in ambient storage and 28 days in refrigerated storage, addressing cold-chain limitations.
• Preclinical studies showed meaningful potential in herpes zoster ophthalmicus (85% viral load reduction) and basal cell carcinoma (29% tumor size reduction vs. placebo, 20% vs. 5-Fluorouracil).
• The licensing agreement with MiMedx for the FleX Product includes potential milestone payments up to $69.55 million and mid-single digit royalties, providing a potential source of non-dilutive funding.
• An established real-world tolerability record with over 200,000 applications of platform-developed products for wound care and dermatology without a single adverse event reported to the FDA, supporting future regulatory submissions and patient confidence.
• Strong intellectual property portfolio with 13 issued U.S. patents and multiple pending applications, expected to provide coverage for lead product candidates into the 2040s.
• A capital-efficient operating model leverages expert consultants and outsourced manufacturing to minimize fixed overhead and preserve capital for clinical development.
• The company is strategically positioned to capitalize on market disruption and patent expirations in dermatology and antifungal markets by introducing differentiated, formulation-driven therapies.
• The Marburg vaccine candidate may qualify for multiple FDA expedited programs, including Fast Track designation, Priority Review, and a Tropical Disease Priority Review Voucher (PRV), potentially valued between $80 million and $120 million.
• The Marburg vaccine candidate targets a Category A biological threat, potentially eligible for multi-year government procurement contracts from agencies like BARDA and the Department of Defense, with historical benchmarks suggesting annual revenues of $100 million to $300 million.

Negatives

• The company has incurred significant net losses, including $1.57 million for the six months ended June 30, 2025, and $1.77 million for the year ended December 31, 2024, leading to an accumulated deficit of $20.76 million as of June 30, 2025.
• The consolidated financial statements express 'substantial doubt' about the company's ability to continue as a going concern due to insufficient capital to fund its drug development plans.
• Existing cash and cash equivalents of $3.19 million as of June 30, 2025, are estimated to fund operating expenses and capital expenditure requirements only into the fourth quarter of 2025, indicating a very short cash runway.
• A material weakness in internal control over financial reporting related to the accounting for stock-based compensation was identified, which could lead to material misstatements.
• The company has a limited operating history and has generated minimal revenues from operations, with no revenue from device sales in the prior two fiscal years.
• The direct listing process is less typical than an underwritten initial public offering, lacking a book-building process, price stabilization, and underwriters assuming risk, which could lead to greater price volatility and uncertain trading volume.
• Most existing shareholders, including directors and officers, have not entered into contractual lock-up agreements (except for a portion of the founder's shares), potentially leading to substantial sales of common stock immediately after listing and adversely impacting the trading price.
• The dual roles of Clear Street LLC as financial advisor and a Registered Stockholder create a potential conflict of interest in the price-setting mechanism.
• The MiMedx agreement's revenue recognition is deferred due to unpredictable outcomes and timelines of the FDA approval process for the FleX Product, delaying potential revenue streams.
• The onychomycosis market faces challenges such as lack of awareness, need for confirmed diagnosis, and expensive treatments often not covered by insurance, limiting patient uptake.
• Current topical onychomycosis therapies have limited efficacy, with complete cure rates often below 20%, and oral alternatives carry systemic risks like hepatotoxicity.
• Existing eczema treatments, such as injectable biologics (e.g., Dupixent) and newer biological topicals (e.g., JAK inhibitors like Vtama), are associated with high costs, systemic immunosuppression, and poor safety profiles (black-box warnings).
• The preclinical immunogenicity study for the intranasal Marburg vaccine candidate in animal models has inherent limitations (anatomical differences, interspecies variability, administration challenges), meaning a lack of measurable immune response would not necessarily preclude further human development but adds uncertainty.
• A patent dispute with Marc Selner regarding the Hexagen formula, where Selner retained a patent application that may contain overlapping claims, could lead to attempts to prevent commercialization or seek damages/royalties.
• Heavy reliance on third parties for manufacturing and clinical trials exposes the company to risks related to compliance, supply, quality, and potential delays.
• Operating as a public company will incur increased legal, financial, and compliance costs, and may divert management's attention from core business activities.
• The founder's significant ownership (over 50%) makes the company a 'controlled company,' allowing it to rely on exemptions from certain Nasdaq corporate governance requirements, which could reduce protections for other shareholders.
• The amended certificate of incorporation includes a provision renouncing the company's interest in certain corporate opportunities, potentially allowing directors/officers to pursue competing ventures.

Risks

• We expect to incur additional losses for the foreseeable future, and it is possible we may never achieve or maintain profitability. Our consolidated financial statements therefore express substantial doubt about our ability to continue as a going concern.
• We have a limited operating history and there are inherent uncertainties and risks in pharmaceutical and medical device product development and commercialization.
• If we fail to obtain or generate the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.
• Even if we can raise additional funding, we have in the past and may in the future enter into financing agreements that lead to increased dilution, and which will result in sales of our common stock in the open market, which could adversely impact the trading price of our common stock.
• We identified a material weakness in our internal control over the accuracy of our financial reporting. Any failure to maintain an effective control over financial reporting may result in material misstatements of our consolidated financial statements.
• We expect to increase the size of our organization in the future, and we may experience difficulties in managing this growth. If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.
• We rely upon and intend to continue to rely upon third parties to manufacture our medical devices and drug candidates including for pre-clinical testing, clinical testing, and commercialization. Commercialization of any of our drug candidates and/or medical devices could be stopped, delayed, or made less profitable if those third parties fail to maintain compliance with government regulators, fail to provide us with sufficient quantities of drug product, devices, or device components, or fail to do so at acceptable quality levels or prices.
• Our business is dependent on the successful development, regulatory approval, and commercialization of our products, product candidates and/or future products and product candidates.
• Clinical trials and preclinical studies are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes.
• Failure to comply with government regulations could adversely affect our business.
• If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.
• Obtaining approval of a new device or drug is lengthy, expensive, and inherently uncertain.
• Issued patents covering our current or future products or product candidates could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.
• If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
• Laws, rules and regulations that protect the privacy and security of personal information may increase our costs, limit our ability to collect and use that information, and subject us to liability if we are unable to fully comply with such laws, rules and regulations.
• We may become subject to claims or legal proceedings alleging that we are infringing, misappropriating or otherwise violating the intellectual property rights of others.
• Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated as a result of noncompliance with these requirements.
• Cybersecurity breaches, attacks and other similar incidents, as well as other disruptions, could compromise our confidential and proprietary information, including personal information, and expose us to liability and regulatory fines, increase our expenses, or result in legal or regulatory proceedings, which could cause our business and reputation to suffer.
• Our listing differs significantly from an underwritten initial public offering.
• The public price of our common stock, upon listing on Nasdaq, may have little or no relationship to the historical sales prices of our common stock in private transactions.
• An active trading market may not develop or continue to be liquid and the market price of shares of our common stock may be volatile.
• Sales of substantial amounts of our common stock in the public markets by our founder, affiliates, or non-affiliates, or the perception that such sales might occur, could reduce the price that our common stock might otherwise attain.
• We expect to be a controlled company within the meaning of the corporate governance rules of Nasdaq and, as a result, we qualify for exemptions from certain corporate governance requirements. Although we do not currently intend to rely on any such exemptions, we may do so in the future and if we utilize any of the exemptions, you will not have the same protections as those afforded to stockholders of companies that are subject to such governance requirements.
• Because of his significant ownership of our common stock, our founder has substantial control over our business, and his interests may differ from our interests or those of our other shareholders.
• Our amended and restated certificate of incorporation will contain a provision renouncing our interest and expectancy in certain corporate opportunities which may adversely affect our performance.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.
• The requirements of being a public company may strain our resources, divert managements attention, and affect our ability to attract and retain qualified board of director members.
• If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired.
• Our amended and restated bylaws will require exclusive forum in certain courts in the State of Delaware or the federal district courts of the United States for certain types of lawsuits that may have the effect of discouraging lawsuits against our directors and officers.
• We may not be able to maintain a listing of our common stock on Nasdaq.

Future Outlook

The company expects to incur additional losses for the foreseeable future due to increased research and development costs for later-stage clinical trials. Substantial additional funding will be required to support ongoing drug development and operations, with plans to access capital markets through equity and/or debt financing and strategic collaborations. The current cash and cash equivalents are estimated to fund operations only into the fourth quarter of 2025. The company plans to advance to Phase 3 trials for moderate-to-severe eczema and onychomycosis following the completion of the current Phase 2-equivalent trial, and intends to conduct additional nonclinical and clinical studies in parallel. A preclinical immunogenicity study for the intranasal Marburg vaccine candidate in animal models is planned before the end of 2025, with subsequent Phase 1 and Phase 2 clinical trials expected if the IND filing is successful. The Marburg vaccine candidate is believed to qualify for FDA expedited programs. The company aims to deepen its network of strategic partners, expand technology platform indications, and pursue regulatory milestones for broader commercialization, while continuing to license medical device technologies for near-term revenue.

Management Comments

• "We believe these early findings support our view that the underlying antimicrobial and anti-inflammatory properties of our formulation may have broad therapeutic potential across multiple forms of dermatitis, including atopic, irritant, and contact subtypes."
• "We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs."
• "We believe this initiative highlights our platforms versatility and its potential to unlock new therapeutic categories beyond dermatology."
• "We believe this reduces the amount of cash needed for internal operations, reduces waste and results in a larger proportion of available capital that can be spent toward furthering clinical development."
• "We believe such signals, along with PHMBs well-documented antimicrobial and anti-inflammatory properties, which have been validated by scientific literature and in-vivo studies, form a sound scientific basis for cross-indication effectiveness across these two dermatologic conditions."
• "We believe this hybrid model of licensing and internal drug development positions us to grow while minimizing capital risk."
• "Our ability to generate non-dilutive cash flow from commercial device agreements is designed to support our pharmaceutical programs and extend our operational runway."
• "We believe this favorable track record in real-world uses supports higher likelihoods of success for future regulatory submissions and provides a strong foundation for physician and patient confidence as we advance our therapeutic programs."
• "We believe this procurement history provides a relevant benchmark for the potential commercial pathway of our investigational intranasal Marburg virus vaccine, which targets a similarly classified Category A pathogen with high mortality and recognized potential for weaponization."
• "We believe this shift creates an opportunity to introduce differentiated, formulation-driven therapies into markets with stagnant innovation and increasing generic pressure."

Industry Context

The company operates in the advanced wound care, atopic dermatitis (eczema), onychomycosis, and vaccine markets. The global advanced wound care market is projected to grow from $18.72 billion in 2024 to $30.76 billion by 2034, driven by unmet needs for products with longer duration, less cytotoxicity, and better microbial protection. The global atopic dermatitis market is expected to grow from $12.7 billion in 2024 to $19.5 billion by 2034, with a significant portion being moderate-to-severe cases. Current leading therapies like Dupixent are injectable and costly, highlighting a demand for non-invasive, effective alternatives. The onychomycosis market, valued at $3.81 billion in 2024, suffers from low treatment-seeking rates due to limited efficacy of topical treatments (often below 20% cure rates) and systemic risks of oral therapies. The vaccine market is expanding, particularly for developing countries, but faces cold-chain logistics challenges. The company's thermostable, intranasal vaccine platform aims to address these issues, with the Marburg vaccine candidate targeting a Category A biological threat, potentially benefiting from government stockpiling and procurement contracts, similar to the anthrax vaccine market which has seen over $2 billion in federal contracts.

Comparison to Industry Standards

• The GX-03 topical antifungal product candidate for onychomycosis is designed to overcome the limitations of current topical therapies, such as Jublia (efinaconazole), which are associated with long treatment durations, low complete cure rates (often below 20%), and limited nail bed penetration. It also aims to avoid the systemic risks (e.g., hepatotoxicity, drug interactions, liver monitoring) associated with oral antifungals like terbinafine (LAMISIL).
• The GX-03/Hexagen drug candidate for moderate-to-severe eczema is positioned as a non-steroidal, non-injectable, and non-biologic immunotherapy. This contrasts with leading therapies like Dupixent (dupilumab), an injectable biologic with over $14.5 billion in global net sales in 2024, which faces barriers for certain patient populations due to its injectable format and systemic immunosuppression. It also aims to offer a better profile than newer biological topicals like JAK inhibitors (e.g., Vtama) that are hindered by high cost and poor safety profiles (black-box warnings).
• The intranasal Marburg virus vaccine candidate, with its thermostability features and needle-free delivery, offers operational advantages over traditional injectable vaccines that require deep-frozen storage and complex cold-chain logistics. This innovation is particularly relevant for distribution in low-resource settings and remote military outposts, addressing a significant unmet need in global immunization coverage. The potential for multi-year government procurement contracts is benchmarked against the U.S. government's historical relationship with Emergent BioSolutions for the anthrax vaccine (BioThrax), which has generated over $2 billion in cumulative federal contracts and recent awards exceeding $200 million per year.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings from time to time in the ordinary course of business, but currently has no reason to believe that the ultimate resolution of any known legal proceeding will have a material adverse effect on its financial position, liquidity, or results of operations.
• A derivation proceeding was filed in 2017 before the USPTO against Marc Selner, alleging improper filing of a patent application for an invention conceived by Bradley Burnam. While the USPTO Patent Trial and Appeal Board concluded Mr. Burnam independently conceived his invention, it did not cancel Selner's patent application. The U.S. Court of Appeals for the Federal Circuit affirmed this decision, allowing Selner to retain the patent application. This patent application may contain overlapping claims with the Hexagen formula, and Selner may attempt to prevent commercialization or seek damages/royalties. The company would vigorously defend its rights, but success is not assured.

Related Party Transactions

• Certain investors in the Regulation A offering granted a voting proxy to CEO Bradley Burnam, which will terminate upon the effectiveness of this registration statement.
• The company expects to enter into indemnification agreements with each of its directors and executive officers.
• A registration rights agreement will be entered into with Bradley Burnam, granting him rights to request registration of his shares and participate in certain registered offerings.
• A stockholders agreement will be entered into with Bradley Burnam and BEB Holdings LLC, granting the controlling shareholder certain consent rights over significant corporate actions, including mergers, asset sales, equity issuances, and senior management decisions, as long as he beneficially owns at least 10% of outstanding common stock.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises (e.g., GEM agreement, equity financings) and increased stock price volatility due to the direct listing structure and limited lock-up agreements for most existing shareholders. The founder's controlling interest may limit the influence of other shareholders.
• Employees will be impacted by the company's growth, with plans to hire additional personnel. Equity incentive plans are in place, and the CEO's compensation structure is being updated.
• Customers and patients could benefit from new, effective, and potentially safer treatments for dermatological conditions like eczema and onychomycosis, as well as needle-free, thermostable vaccines for infectious diseases.
• Suppliers and creditors may face risks due to the company's 'going concern' doubt and reliance on future capital raises to fund operations.
• Regulatory bodies will continue to oversee the company's compliance with extensive FDA and other healthcare regulations, which are critical for product approvals and commercialization.

Next Steps

• Advance to Phase 3 trials for moderate-to-severe eczema and onychomycosis.
• Conduct additional nonclinical and clinical studies (PK max-use, healthy volunteer exposure trials) in parallel with Phase 3 trials.
• Conduct a preclinical immunogenicity study of the intranasal Marburg vaccine candidate in a live animal model before the end of 2025.
• Initiate Phase 1 and Phase 2 clinical trials for the Marburg vaccine if the IND filing is successful.
• Submit a Biologics License Application (BLA) to the FDA for the Marburg vaccine.
• Pursue FDA expedited programs (Fast Track, Priority Review, Tropical Disease PRV) for the Marburg vaccine.
• Deepen the network of strategic partners and expand the indications addressed by the technology platform.
• Pursue regulatory milestones that support broader commercialization opportunities both in the U.S. and internationally.
• Identify potential partners for distribution of AtopX (GX-03/Hexagen for dermatitis) outside the United States.
• Secure an exclusive partner to market XEAL (antimicrobial gauze) in the United States and globally.
• MiMedx is expected to finalize in-vivo/in-vitro data for the FleX Product and submit it for De Novo review by the end of 2025.
• Implement a remediation plan for the identified material weakness in internal control over financial reporting, including hiring personnel or engaging experts.
• Hire additional managerial, operational, sales, marketing, financial, and other personnel to manage anticipated growth.
• Adopt a new employment agreement with CEO Bradley Burnam, effective upon the direct listing.
• Adopt the 2025 Omnibus Incentive Plan, effective upon the direct listing.
• Adopt a non-employee director compensation policy, effective upon the direct listing.
• Enter into a registration rights agreement with Bradley Burnam.
• Enter into a stockholders agreement with Bradley Burnam and BEB Holdings LLC.

Key Dates

Recommendation

The company faces significant financial distress, evidenced by recurring losses and 'substantial doubt' about its ability to continue as a going concern. While it possesses promising technology and pipeline candidates, the immediate need for substantial capital, coupled with the inherent volatility and lack of price stabilization mechanisms of a direct listing, presents a high-risk investment profile. The identified material weakness in financial reporting and the founder's controlling interest further add to governance concerns. The potential for significant dilution from future capital raises and open market sales by non-locked-up shareholders could severely depress the stock price. A seasoned investor would likely view this as a highly speculative venture with considerable downside risk in the near term.

Keywords

Pharmaceutical, Medical Device, Dermatology, Eczema, Onychomycosis, Vaccine, PermaFusion, Hexagen, PHMB, Direct Listing, Nasdaq, Biopharmaceutical, Clinical Trials, Drug Development, Intellectual Property, Corporate Governance, Risk Management, Capital Raise